0001437749-19-024347.txt : 20191212
0001437749-19-024347.hdr.sgml : 20191212
20191212202707
ACCESSION NUMBER: 0001437749-19-024347
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191210
FILED AS OF DATE: 20191212
DATE AS OF CHANGE: 20191212
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rice Michael
CENTRAL INDEX KEY: 0001389512
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36362
FILM NUMBER: 191283088
MAIL ADDRESS:
STREET 1: C/O BIOLIFE SOLUTIONS, INC.
STREET 2: 171 FRONT STREET
CITY: OWEGO
STATE: NY
ZIP: 13827
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIOLIFE SOLUTIONS INC
CENTRAL INDEX KEY: 0000834365
STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
IRS NUMBER: 943076866
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3303 MONTE VILLA PARKWAY
STREET 2: SUITE 310
CITY: BOTHELL
STATE: WA
ZIP: 98021
BUSINESS PHONE: 4254011400
MAIL ADDRESS:
STREET 1: 3303 MONTE VILLA PARKWAY
STREET 2: SUITE 310
CITY: BOTHELL
STATE: WA
ZIP: 98021
FORMER COMPANY:
FORMER CONFORMED NAME: BIOLIFE SOLUTION INC
DATE OF NAME CHANGE: 20030113
FORMER COMPANY:
FORMER CONFORMED NAME: CRYOMEDICAL SCIENCES INC
DATE OF NAME CHANGE: 19920703
4
1
rdgdoc.xml
FORM 4
X0306
4
2019-12-10
0000834365
BIOLIFE SOLUTIONS INC
BLFS
0001389512
Rice Michael
C/O BIOLIFE SOLUTIONS, INC.
3303 MONTE VILLA PARKWAY, SUITE 310
BOTHELL
WA
98021
1
1
President & CEO
Common Stock
2019-12-10
5
G
0
7000
0
D
168014
D
Common Stock
2019-12-10
4
M
0
10000
1.12
A
178014
D
Common Stock
2019-12-10
4
S
0
10000
15.37
D
168014
D
Common Stock
2019-12-12
4
M
0
10247
1.12
A
178261
D
Common Stock
2019-12-12
4
S
0
10247
15.11
D
168014
D
Employee Stock Option
1.12
2019-12-10
4
M
0
10000
0
D
2011-02-25
2021-02-25
Common Stock
10000
10247
D
Employee Stock Option
1.12
2019-12-12
4
M
0
10247
0
D
2011-02-25
2021-02-25
Common Stock
10247
0
D
This transaction represents a charitable donation to a third party. No value was received for the gifted shares.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2019.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.35 to $15.41, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.99 to $15.18, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The reporting person's Form 4 filed on November 14, 2019 reported a remainder of 10,247 derivative securities when in fact the remainder was 20,247 derivative securities beneficially owned by the reporting person.
/s/ Michael Rice
2019-12-12